semaglutide phase 1 GLP-1 agonist clinical pipeline 2026: drugs and 2 FDA Approves First ORAL GLP-1

It is not a prescription medication and cannot be legally prescribed by Canadian physicians for treatment purposes

If you begin GLP-1 therapy, contact your GP promptly if you experience severe abdominal pain (which could indicate pancreatitis), persistent nausea or vomiting, symptoms of thyroid problems (such as a lump in the neck, hoarseness, or difficulty swallowing), or any other concerning symptoms

According to the letter, the product is considered an unapproved drug because it is promoted for drug-like uses on the company's website, including the following: Recalls & Warnings January 28, 2020 Weight Supplement Contains Hidden Drug On January 13, 2020, the FDA issued a warning letter to Wave Miami, LLC because the company's weight loss supplement, Lipro Dietary Capsule was found to contain the prescription medication tadalafil

Rare but serious side effects : These include pancreatitis or gallbladder disease, and any concerning symptoms should be discussed with your prescribing healthcare provider immediately